DLL3 and neoplasm: Specific tumor biomarkers, such as delta‐like ligand 3 (DLL3) and schlafen11 (SLFN11), may enable the selection of more efficacious, novel immunomodulating targeted treatments like bispecific T‐cell engaging monoclonal antibodies (tarlatamab) and chemotherapy with PARP inhibitors.